SCHEMBL15173003

SCHEMBL15173003

COc1cccc(-c2cc3nccc(-c4ccc(OC5CCOCC5)c(C#N)c4)c3o2)c1

nearest known ligand 0.53

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 20/20 0.53
IKBKE Q14164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15173039 0.92 TBK1 (0.55) TBK1IKBKE
SCHEMBL15172931 0.89 TBK1 (0.52) TBK1IKBKE
SCHEMBL15173157 0.87 TBK1 (0.56) TBK1IKBKE
SCHEMBL15173033 0.85 TBK1 (0.67) TBK1IKBKE
SCHEMBL18348025 0.85 TBK1 (0.56) TBK1IKBKE
SCHEMBL18348024 0.84 TBK1 (0.56) TBK1IKBKE
SCHEMBL15174761 0.84 TBK1 (0.61) TBK1IKBKE
SCHEMBL15173325 0.84 TBK1 (0.54) TBK1IKBKE
SCHEMBL16336236 0.84 TBK1 (0.55) TBK1IKBKE
SCHEMBL15173112 0.83 TBK1 (0.56) TBK1IKBKE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2812337-B1 FURO [3, 2 - B]PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS MERCK PATENT GMBH (DE) 2016-09-07 EP claimed
US-9045493-B2 Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives MERCK PATENT GMBH (DE) 2015-06-02 US claimed
US-20150005284-A1 Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives MERCK PATENT GMBH (DE) 2015-01-01 US claimed
EP-2812337-A1 FURO [3, 2 - B]- AND THIENO [3, 2 - B]PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS Merck Patent GmbH (DE) 2014-12-17 EP claimed
WO-2013117285-A1 FURO [3, 2 - B] - AND THIENO [3, 2 - B] PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS MERCK PATENT GMBH (DE) 2013-08-15 WO claimed
EP-2812337-B1 FURO [3, 2 - B]PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS MERCK PATENT GMBH (DE) 2016-09-07 EP disclosed
US-9045493-B2 Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives MERCK PATENT GMBH (DE) 2015-06-02 US disclosed
US-20150005284-A1 Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives MERCK PATENT GMBH (DE) 2015-01-01 US disclosed
EP-2812337-A1 FURO [3, 2 - B]- AND THIENO [3, 2 - B]PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS Merck Patent GmbH (DE) 2014-12-17 EP disclosed
WO-2013117285-A1 FURO [3, 2 - B] - AND THIENO [3, 2 - B] PYRIDINE DERIVATIVES AS TBK1 AND IKK INHIBITORS MERCK PATENT GMBH (DE) 2013-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005284-A1 Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives TBK1, NFKBIA, IKBKG TBK1 1/4885IKBKE 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.